Simulations Plus (SLP) Aktsia Kursus
Simulations Plus Kursus
Viimase 19 aasta jooksul kasvas Simulations Plus käive 14,7 % aastas ja jõudis 79,18 M USD-ni. Kasum aktsia kohta kasvas 15,0 % aastas viimase 18 aasta jooksul. Simulations Plus netomarginaal −81,7 % on langenud võrreldes 21,1 %-ga mõni aasta tagasi. Tänase hinna juures on dividenditootlus umbes 0,97 %. Väljamaksesuhe on umbes 37 % kasumist. Simulations Plus 12 kuu konsensuse hinnasiht on 18,50 USD, umbes üle kurssi 0,0 %. 12 analüütikust 0 soovitab osta — üldine konsensus on Müü.
Simulations Plus aktsiahinnad
Hangi need andmed Eulerpool API kaudu
100 000 päringut/kuus tasuta · krediitkaarti pole
Simulations Plus ärimudel ja aktsia analüüs
Korduma kippuvad küsimused Simulations Plus aktsia kohta
Simulations Plus Inc is primarily active in the pharmaceutical and biotechnology industries. With a focus on simulation software and consulting services, the company provides cutting-edge solutions for drug discovery and development. Simulations Plus Inc's expertise in modeling and simulation technologies helps pharmaceutical companies optimize their drug formulation and dosage strategies. By leveraging their industry-leading software platforms, Simulations Plus Inc supports the efficient research and development of new therapies, enhancing the overall success and effectiveness of pharmaceutical companies.
The main competitors of Simulations Plus Inc in the market include Certara, Inc and Dassault Systèmes.
The business model of Simulations Plus Inc revolves around providing software and consulting services for pharmaceutical research and development. As a leading provider in the field of drug discovery and development, Simulations Plus Inc aims to enhance the efficiency and effectiveness of the pharmaceutical industry through their innovative solutions. By utilizing computer modeling and simulation software, the company assists in predicting and optimizing drug properties, interactions, and outcomes. This enables scientists and researchers to make informed decisions throughout the drug development process, leading to improved efficacy, safety, and reduced costs. Simulations Plus Inc's comprehensive solutions cater to the needs of pharmaceutical companies, regulatory agencies, and academia worldwide.
Simulations Plus Inc is a leading provider of simulation and modeling software for the pharmaceutical and biotechnology industries. Established in 1996, the company has amassed extensive expertise in the field. Simulations Plus Inc has developed a strong reputation for its cutting-edge technology and innovative solutions, helping pharmaceutical companies optimize drug discovery and development processes. With a focus on increasing efficiency and reducing costs, Simulations Plus Inc has become a trusted partner for numerous organizations worldwide. The company's commitment to excellence has earned them recognition and a loyal customer base. Simulations Plus Inc continues to drive advancements in the industry, delivering impactful software solutions that streamline drug development.
Simulations Plus Inc has achieved significant milestones throughout its history. Some notable accomplishments include the development and release of their industry-leading software solutions, such as GastroPlus™ and DDDPlus™, which have gained widespread recognition and adoption in the pharmaceutical industry. The company has also formed strategic partnerships and collaborations with top pharmaceutical companies, further establishing its presence and credibility in the market. Additionally, Simulations Plus Inc has a strong track record of achieving consistent revenue growth and delivering value to its shareholders. These achievements reflect the company's commitment to innovation, excellence, and meeting the evolving needs of the life sciences industry.
Simulations Plus Inc is primarily present in the United States.
Simulations Plus Inc represents values of innovation, scientific excellence, and customer satisfaction. With a corporate philosophy focused on advancing pharmaceutical research and enhancing drug development, Simulations Plus Inc strives to provide cutting-edge software and consulting services. By combining advanced technologies and domain knowledge, the company facilitates cost-effective and efficient drug discovery and development processes. Simulations Plus Inc is committed to delivering high-quality solutions, fostering collaborative relationships, and continuously improving its products and services.
Analüütikud määravad Simulations Plus aktsiale keskmiseks hinnasihi 18,50 USD (mediaan: 18,50 USD), mis on +0,0 % viimase hinna suhtes. Konsensus põhineb 12 analüütiku hinnangul.
12 analüütikut hindavad praegu Simulations Plus aktsiat: 0 soovitab osta, 7 hoida ja 5 müüa. 2026. aastaks ootavad analüütikud, et Simulations Plus teenib tulu 81,80 M USD ja kasumit aktsia kohta 0,82 USD.
Praeguse kursiga kaubeldakse Simulations Plus aktsiaga 16,53 EUR (18,50 USD) juures.
Simulations Plus aktsia (SLP) on noteeritud 1 börsil, sh: NASDAQ (SLP).
Simulations Plus Inc. is a leading company in the field of simulation technology and software development. It provides solutions for researchers and experts in various industries, including biotechnology, pharmaceuticals, agriculture, food technology, and more. The company offers a range of products and tools for data analysis and innovative strategy development to bring new products and applications to the market. Some of its notable products include PK-SIM, MoBi, ADMET Predictor, GastroPlus, DILIsym, and MedChem Studio. Simulations Plus also offers solutions for the agricultural sector, such as Cartagenia, Crop Laptop, and Dose Response Toxicology. The company provides training and support to its customers, aiming to optimize their business processes. Its business model focuses on processing and analyzing large data sets to provide relevant insights and support decision-making processes. Simulations Plus aims to expand into new markets and develop products based on the latest technological advancements.
oodatav Simulations Plus käive on 81,80 M USD. See näitaja põhineb praegusel finantsandmetel ja peegeldab ettevõtte äritulemuseid.
oodatav Simulations Plus kasum on 16,48 M USD. Netokasum peegeldab ettevõtte kasumlikkust pärast kõigi kulude mahaarvamist.
Võrdlusarvud hinna ja kasumiga (P/E) Simulations Plus jaoks on praegu 22,69. P/E-suhtarv võrdleb praegust aktsiahinnad kasumiga aktsia kohta ja aitab investoritel hinnata Simulations Plus aktsia väärtust.
Kursuse ja müügimahu suhe (P/S) Simulations Plus jaoks on praegu 4,57. P/S-suhtarv võrdleb börsikapitalisatsooni aastase tuluga ja teenib hindamismõõdikuna Simulations Plus aktsia jaoks.
Eulpooli kvaliteedinäitaja Simulations Plus jaoks on 4/10.
Simulations Plus ISIN on US8292141053. ISIN (rahvusvaheline väärtpaberi identifitseerimise number) on väärtpaberite globaalne unikaalne tuvastaja.
Simulations Plus WKN on 924294. WKN (Wertpapierkennnummer) on kuuekohaline saksa väärtpaberi identifitseerimise number.
Simulations Plus ticker on SLP. Ticker-sümbol kasutatakse Simulations Plus aktsiate kauplemiseks börsil.
Simulations Plus aktsia
Simulations Plus konkurendid
Simulations Plus Börsiticker
Simulations Plus FIGI
Kõik teised näitajad ja analüüsid Simulations Plus kohta sügavamalt
Meie Simulations Plus-aktsia analüüs sisaldab olulisi finantsnäitajaid, nagu käive, kasum, P/E suhe, P/S suhe, EBIT, samuti teavet dividendi kohta. Lisaks käsitleme aspekte nagu aktsiad, turukapitalisatsioon, võlad, omakapital ja kohustused ettevõttes Simulations Plus. Kui otsite nende teemade kohta põhjalikumat teavet, pakume teile meie alamlehtedel üksikasjalikke analüüse: